NEW YORK, April 3, 2026 /PRNewswire/ -- As Congress reviews the President's federal budget proposal for Fiscal Year (FY) 2027, the three leading national Parkinson's advocacy organizations — on behalf of the 1.2 million Americans living with Parkinson's and related conditions — urge lawmakers to increase investment in the National Institutes of Health (NIH). The NIH is the primary driver of biomedical research progress, for the benefit of the health of Americans. This budget request, which inclu

SNOQUALMIE, Wash.--(BUSINESS WIRE)--Spacelabs Healthcare today announced that it has signed an agreement with DEPTH Health, Inc., a leader in patient traffic flow optimization technology, that will allow DEPTH Health to provide hospitals and health systems the Rothman Index® through its DEPTH’s Real-Time Advisor for Clinical Expert Routing (RACER™) offering. Spacelabs Healthcare’s Rothman Index is an advanced application that is designed to help healthcare providers identify subtle changes in a

HANGZHOU, China, April 3, 2026 /PRNewswire/ -- A team led by principal investigators Bobo Dang and Ting Zhou at Westlake University/Westlake Laboratory reported in Science a high-throughput platform for engineering fast-acting covalent protein therapeutics. Their work, titled "A high-throughput selection system for fast-acting covalent protein drugs," opens new avenues for next-generation biologics. Continue Reading Fig. 1. The principle for developing fast-acting covalent proteins via comprehe

DELRAY BEACH, Fla., April 3, 2026 /PRNewswire/ -- According to MarketsandMarkets™, the Next Generation Drug Conjugates Market is projected to grow from about USD 15.75 billion in 2026 to USD 42.55 billion by 2035, at a CAGR of 11.7%. Browse 260 market data Tables and 60 Figures spread through 270 Pages and in-depth TOC on "Next Generation Drug Conjugates Market - Global Forecast to 2035" Next Generation Drug Conjugates Market Size & Forecast: Market Size Available for Years: 2026–2035 2026 Mark

Liechtenstein-based biotech company reports significant lifespan extension in C. elegans and advances toward preclinical development with CRO partners We built a compound series with the strongest reported SIRT6 activation in the literature. The patent filing protects this work as we move into preclinical development.” — Andraz Zurman, Co-Founder, Virella Ltd SCHAAN, LIECHTENSTEIN, April 3, 2026 / EINPresswire.com / -- Virella Ltd, a European biotech company developing small-molecule SIRT6 acti

Notifications have no immediate effect on the listing or trading of the Company's securities on Nasdaq Nasdaq has provided the Company until September 29, 2026 to regain compliance with both requirements The Company is actively evaluating actions to regain compliance, with a clear focus on initiatives that are aligned with and supportive of long-term shareholder value CAMBRIDGE, Mass., April 3, 2026 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense" or the "Company"), a la

LOS ANGELES, April 3, 2026 /PRNewswire/ -- As tick activity increases during the warmer months, Better Life Science is highlighting prevention, early response and access to at-home Lyme disease testing through its Tick Bite Hero brand. With more people spending time outdoors this spring, Better Life Science is reminding consumers that tick bites often go unnoticed, making prevention and fast response especially important. Public health guidance recommends using repellent, checking for ticks aft

ORLANDO, Fla., April 3, 2026 /PRNewswire/ -- During the second annual National Youth Heart Screening Day, more than 50 children and young adults were identified at risk for sudden cardiac arrest (SCA) through a nationwide effort led by Parent Heart Watch. Held during Heart Month, the initiative brought together 16 organizations and 3 co-partners across 21 sites in 14 states, providing free heart screenings and life-saving education nationwide. The effort was supported by Cardiac Insight and Liqu

-- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. “We are thrilled to welcome Kim to our Board of Directors,” said David Meek

ROSEMONT, Ill., April 3, 2026 /PRNewswire/ -- Oral and oropharyngeal cancers account for roughly one death every hour in the United States, yet outcomes improve substantially when the disease is found early. During April's Oral Cancer Awareness Month, the American Association of Oral and Maxillofacial Surgeons (AAOMS) is encouraging the public to take two simple steps: perform a monthly self-exam and schedule regular screenings with a healthcare provider. National statistics illustrate why aware